Introduction {#section1-1559325820931290}
============

Pancreatic cancer is a highly lethal disease with a very poor prognosis.^[@bibr1-1559325820931290]^ An estimated 458 918 new cases of pancreatic cancer were diagnosed and 432 242 patients died of this disease worldwide in 2018.^[@bibr2-1559325820931290]^ Surgical resection is the only treatment to offer a chance of curative therapy, and adjuvant chemotherapy has been shown to improve survival outcomes.^[@bibr3-1559325820931290]^ Immunotherapy including immune checkpoint blockade and vaccine therapy has been investigated in clinical trials and shows promising effects.^[@bibr4-1559325820931290]^ Despite treatment advances, the prognosis of pancreatic cancer is dismal, with a 5-year survival rate as low as 6% in the United States.^[@bibr5-1559325820931290]^ Therefore, it is imperative to identify reliable and sensitive prognostic factors to aid in individualized treatment decision-making and survival outcome prediction for patients with pancreatic cancer.

Growing evidence indicates that cancer-associated inflammation and immune cells are involved in cancer progression and can promote cancer development.^[@bibr6-1559325820931290],[@bibr7-1559325820931290]^ Many cancer-related inflammatory biomarkers derived from peripheral blood samples have been investigated as effective prognostic factors in various cancers.^[@bibr8-1559325820931290],[@bibr9-1559325820931290]^ These serum parameters include, but are not limited to, modified Glasgow prognostic score,^[@bibr10-1559325820931290]^ platelet-to-lymphocyte ratio,^[@bibr11-1559325820931290]^ systemic immune-inflammation index,^[@bibr12-1559325820931290]^ and C-reactive protein to albumin ratio (CAR).^[@bibr13-1559325820931290]^ The CAR is a novel inflammation-based parameter that has been evaluated as a potential prognostic factor in pancreatic cancer.^[@bibr14-1559325820931290][@bibr15-1559325820931290][@bibr16-1559325820931290][@bibr17-1559325820931290][@bibr18-1559325820931290][@bibr19-1559325820931290][@bibr20-1559325820931290][@bibr21-1559325820931290][@bibr22-1559325820931290][@bibr23-1559325820931290]-[@bibr24-1559325820931290]^ However, the results of previous relevant studies ^[@bibr14-1559325820931290][@bibr15-1559325820931290][@bibr16-1559325820931290][@bibr17-1559325820931290][@bibr18-1559325820931290][@bibr19-1559325820931290][@bibr20-1559325820931290][@bibr21-1559325820931290][@bibr22-1559325820931290][@bibr23-1559325820931290]-[@bibr24-1559325820931290]^ were inconsistent. To quantitatively and systematically clarify this issue, we identified relevant studies and performed a meta-analysis of the prognostic value of CAR in patients with pancreatic cancer.

Materials and Methods {#section2-1559325820931290}
=====================

Guidelines and Ethics Statement {#section3-1559325820931290}
-------------------------------

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.^[@bibr25-1559325820931290]^ All analyses were based on previously published studies; thus, ethics approval and informed consent were not required for this study.

Search Strategy {#section4-1559325820931290}
---------------

A comprehensive and systematic literature search was conducted using PubMed, Embase, Web of Science, and Cochrane Library databases. The search strategies were the combinations of the following keywords: ("C-reactive protein/albumin ratio" or "C-reactive protein to albumin ratio" or "C-reactive protein-to-albumin ratio" or "CRP/Alb ratio") and ("pancreatic cancer" or "pancreatic carcinoma" or "pancreatic adenocarcinoma" or "pancreatic neoplasm" or "pancreatic tumor"). The last search was updated on October 17, 2019. In addition, the reference lists of relevant studies were carefully examined for potential inclusions.

Selection Criteria {#section5-1559325820931290}
------------------

The studies eligible for the meta-analysis met the following inclusion criteria: (1) histological or pathological confirmation of the pancreatic cancer diagnosis; (2) evaluation of CAR before treatment; (3) measurement of CAR using serum-based methods; (4) assessment of the prognostic value of CAR in survival outcomes including overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS); (5) available or calculable hazard ratio (HR) with 95% confidence interval (95% CI);^[@bibr26-1559325820931290],[@bibr27-1559325820931290]^ (6) a CAR cutoff value; and (7) published in the English language. The exclusion criteria were (1) letters, conference abstracts, case reports, or reviews; (2) animal studies; (3) duplicate studies or studies with overlapping patients; (4) studies with insufficient information for analysis; and (5) non-English studies. Overall survival was defined as the date of the first treatment to the date of death.^[@bibr14-1559325820931290]^ Progression-free survival was defined as the time from treatment to the first observation of progression.^[@bibr14-1559325820931290]^ Disease-free survival was defined as the time from treatment to any recurrence or death from any cause.

Data Extraction and Quality Assessment {#section6-1559325820931290}
--------------------------------------

Data from all candidate articles were evaluated and extracted by 2 independent investigators (Q.X. and L.W.) and any discrepancies were resolved by discussion with a third investigator (S.Z.). The following information was extracted: first author, year of publication, country, sample size, age, sex distribution, ethnicity, tumor node metastasis stage, treatment, study design, CAR cutoff value, survival outcomes and HRs with 95% CIs, and study period. The quality of the eligible studies was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS).^[@bibr28-1559325820931290]^ The NOS comprises 3 major aspects: study cohort selection (0-4 stars), study cohort comparability (0-2 stars), and outcome ascertainment (0-3 stars). The maximum NOS score was 9, and studies with NOS scores ≥6 were considered to be of high quality.

Statistical Analysis {#section7-1559325820931290}
--------------------

The association between CAR and prognosis was evaluated by pooling HRs with 95% CIs. An HR \> 1 without overlapping 95% CI suggested that an elevated CAR was correlated with poorer prognosis. The heterogeneity among studies was assessed using Cochran's Q^[@bibr29-1559325820931290]^ and Higgins *I*2 test.^[@bibr30-1559325820931290]^ When significant heterogeneity (*I*2 \>50% and/or *P* \< .10) was observed, a random effect model was adopted; otherwise, a fixed-effect model was applied. Subgroup analyses were conducted to further investigate and detect the source of heterogeneity. Pooled odds ratios (ORs) with 95%CIs were calculated to assess the relationship between CAR and clinicopathological features. Sensitivity analysis was conducted to test the stability of the results by omitting each study in turn. Publication bias was examined using Begg's funnel plots and Egger's tests. All statistical analyses were performed using Stata SE 12.0 (Stata Corporation). A *P* \< .05 was considered statistically significant.

Results {#section8-1559325820931290}
=======

Study Selection and Characteristics {#section9-1559325820931290}
-----------------------------------

The literature selection process is summarized in [Figure 1](#fig1-1559325820931290){ref-type="fig"}. The initial literature retrieval yielded 101 records, with 79 studies remaining after removing duplicate records. Subsequently, 51 studies were discarded following title and abstract screening, and the full texts of 28 studies were further examined. Seventeen studies were excluded after full-text review for insufficient data (n = 13), recruiting overlapping patients (n = 2), not focusing on pancreatic cancer (n = 1), and lack of pretreatment CAR measurement. Finally, the meta-analysis included a total of 11 studies^[@bibr14-1559325820931290][@bibr15-1559325820931290][@bibr16-1559325820931290][@bibr17-1559325820931290][@bibr18-1559325820931290][@bibr19-1559325820931290][@bibr20-1559325820931290][@bibr21-1559325820931290][@bibr22-1559325820931290][@bibr23-1559325820931290]-[@bibr24-1559325820931290]^ comprising 2271 patients. The baseline characteristics of the included studies are shown in [Table 1](#table1-1559325820931290){ref-type="table"}. The studies were published from 2016 to 2019 from 5 countries, including Japan (n = 4),^[@bibr17-1559325820931290],[@bibr19-1559325820931290],[@bibr20-1559325820931290],[@bibr23-1559325820931290]^ China (n = 3),^[@bibr15-1559325820931290],[@bibr16-1559325820931290],[@bibr22-1559325820931290]^ Korea (n = 2),^[@bibr14-1559325820931290],[@bibr21-1559325820931290]^ Italy (n = 1),^[@bibr18-1559325820931290]^ and Austria (n = 1).^[@bibr24-1559325820931290]^ The sample sizes ranged from 43 to 595, with a median of 188. All included studies reported the association between CAR and OS,^[@bibr14-1559325820931290][@bibr15-1559325820931290][@bibr16-1559325820931290][@bibr17-1559325820931290][@bibr18-1559325820931290][@bibr19-1559325820931290][@bibr20-1559325820931290][@bibr21-1559325820931290][@bibr22-1559325820931290][@bibr23-1559325820931290]-[@bibr24-1559325820931290]^ with 3^[@bibr14-1559325820931290],[@bibr19-1559325820931290],[@bibr21-1559325820931290]^ and 2^[@bibr17-1559325820931290],[@bibr20-1559325820931290]^ studies reporting the relationship between CAR and PFS and DFS, respectively. The CAR cutoff values ranged from 0.0003 to 3.85, with a median value of 0.18. Therefore, we used 0.20 for the subgroup analyses. The NOS scores ranged from 6 to 8, with a mean value of 7, indicating that all included studies were of high quality.

![Flow diagram of the study selection process.](10.1177_1559325820931290-fig1){#fig1-1559325820931290}

###### 

Basic Characteristics of Studies Included in Meta-Analysis.

![](10.1177_1559325820931290-table1)

  Author      Year   Country   Sample size   Sex (M/F)   Ethnicity   TNM stage   Treatment                         Age (years) mean/median (range)   Study design    Cutoff value   Survival analysis   Study duration   NOS score
  ----------- ------ --------- ------------- ----------- ----------- ----------- --------------------------------- --------------------------------- --------------- -------------- ------------------- ---------------- -----------
  Lee         2016   Korea     82            49/33       Asian       III-IV      Chemotherapy + targeted therapy   63.5                              Retrospective   0.5            OS, PFS             2011-2014        8
  Wu          2016   China     233           156/77      Asian       III-IV      Chemotherapy                      62 (26-85)                        Retrospective   0.54           OS                  2011-2014        7
  Hang        2017   China     142           92/50       Asian       III-IV      Chemotherapy                      61 (34-86)                        Retrospective   0.156          OS                  2009-2014        7
  Ikeguchi    2017   Japan     43            30/13       Asian       I-III       Surgery                           71.6 (37-88)                      Retrospective   0.04           OS, DFS             2006-2015        8
  Piciucchi   2017   Italy     206           112/84      Caucasian   I-IV        Mixed                             69.9                              Retrospective   1              OS                  NR               6
  Arima       2018   Japan     142           74/68       Asian       NR          Surgery                           69 (37-90)                        Retrospective   0.34           OS, PFS             2004-2014        6
  Fujiwara    2018   Japan     188           115/73      Asian       I-IV        Surgery                           67 (27-84)                        Retrospective   0.004          OS, DFS             2000-2015        7
  Kim         2018   Korea     302           189/113     Asian       III-IV      Chemotherapy + targeted therapy   64 (38-83)                        Retrospective   3.85           OS, PFS             2004-2016        7
  Fan         2019   China     595           380/215     Asian       III-IV      Chemotherapy                      62 (33-84)                        Retrospective   0.18           OS                  2011-2016        8
  Ikuta       2019   Japan     136           76/60       Asian       I-IV        Surgery                           68 (33-86)                        Retrospective   0.09           OS                  2005-2017        7
  Vujic       2019   Austria   202           NR          Caucasian   NR          Surgery                           NR                                Retrospective   0.0003         OS                  2000-2016        6

Abbreviations: DFS, disease-free survival; F, female; M, male; NR, not reported; NOS, Newcastle Ottawa scale; OS, overall survival; PFS, progression-free survival.

Association Between CAR and OS in Pancreatic Cancer {#section10-1559325820931290}
---------------------------------------------------

All 11 included studies (2271 cases) showed the prognostic value of CAR in OS. The pooled results were as follows: HR = 1.84, 95% CI = 1.65 to 2.06, *P* \< .001 ([Figure 2](#fig2-1559325820931290){ref-type="fig"}; [Table 2](#table2-1559325820931290){ref-type="table"}). Subgroup analysis stratified by ethnicity, sample size, treatment, and CAR cutoff values indicated that CAR remained a significant prognostic factor in different subgroups ([Table 2](#table2-1559325820931290){ref-type="table"}).

![Meta-analysis of the associations between the CAR and overall survival in pancreatic cancer.](10.1177_1559325820931290-fig2){#fig2-1559325820931290}

###### 

Effect of CAR on Pancreatic Cancer in Different Subgroups.

![](10.1177_1559325820931290-table2)

  Subgroup                           No. of studies   No. of patients   Effects model   HR (95%CI)         *P*      Heterogeneity   
  ---------------------------------- ---------------- ----------------- --------------- ------------------ -------- --------------- ------
  Overall survival                   11               2271              Fixed           1.84 (1.65-2.06)   \<.001   49.2            .033
  Ethnicity                                                                                                                         
   Asian                             9                1863              Random          1.95 (1.59-2.39)   \<.001   55.3            .022
   Caucasian                         2                408               Fixed           1.65 (1.24-2.21)   .001     13.3            .283
  Sample size                                                                                                                       
   \<200                             6                733               Fixed           1.84 (1.50-2.25)   \<.001   0               .904
   ≥200                              5                1538              Random          1.95 (1.44-2.65)   \<.001   77.9            .001
  Treatment                                                                                                                         
   Surgery                           5                711               Fixed           1.79 (1.46-2.21)   \<.001   0               .646
   Chemotherapy                      3                970               Random          2.25 (1.40-3.62)   .001     84              .002
   Chemotherapy + targeted therapy   2                384               Fixed           1.48 (1.15-1.90)   .002     0               .788
   Mixed                             1                206               --              2.02 (1.27-3.22)   .003     --              --
  Cutoff value of CAR                                                                                                               
   \<0.20                            6                1306              Fixed           1.79 (1.56-2.06)   \<.001   0               .736
   ≥0.20                             5                965               Random          2.04 (1.38-3.03)   \<.001   75.7            .002
   Progression-free survival         3                526               Fixed           1.53 (1.27-1.85)   \<.001   0               .892
   Disease-free survival             2                231               Fixed           1.77 (1.30-2.41)   \<.001   28.9            .236

Abbreviations: CAR, C-reactive protein to albumin ratio; HR, hazard ratio.

Relationship Between CAR and PFS and DFS in Pancreatic Cancer {#section11-1559325820931290}
-------------------------------------------------------------

Three studies^[@bibr14-1559325820931290],[@bibr19-1559325820931290],[@bibr21-1559325820931290]^ (526 patients) reported a correlation between CAR and PFS. As shown in [Figure 3A](#fig3-1559325820931290){ref-type="fig"} and [Table 2](#table2-1559325820931290){ref-type="table"}, the pooled HR and 95% CI were 1.53 and 1.27 to 1.85, respectively (*P* \< .001). Moreover, data extracted from 2 studies^[@bibr17-1559325820931290],[@bibr20-1559325820931290]^ (231 subjects) demonstrated that elevated CAR was associated with poor DFS (HR = 1.77, 95% CI = 1.30-2.41, *P* \< .001; [Figure 3B](#fig3-1559325820931290){ref-type="fig"}; [Table 2](#table2-1559325820931290){ref-type="table"}). Subgroup analysis of PFS and DFS was not performed because of the limited number of studies.

![Meta-analysis of the pooled hazard ratios for patients with high CAR with different survival outcomes. (A) Progression-free survival (PFS) and (B) disease-free survival (DFS).](10.1177_1559325820931290-fig3){#fig3-1559325820931290}

Correlation Between CAR and Clinicopathological Features in Pancreatic Cancer {#section12-1559325820931290}
-----------------------------------------------------------------------------

Six studies^[@bibr15-1559325820931290],[@bibr16-1559325820931290],[@bibr19-1559325820931290],[@bibr22-1559325820931290][@bibr23-1559325820931290]-[@bibr24-1559325820931290]^ reported the relevance of CAR and clinicopathological characteristics including sex (male vs female), tumor location (head vs body or tail), disease stage (metastasis vs locally advanced), and pN stage (N1 vs N0). As shown in [Figure 4](#fig4-1559325820931290){ref-type="fig"} and [Table 3](#table3-1559325820931290){ref-type="table"}, the pooled data indicated that high pretreatment CAR was associated with male sex (OR = 1.38, 95% CI = 1.10-1.74, *P* = .006) but not tumor location (OR = 0.93, 95% CI = 0.72-1.20, *P* = .582), disease stage (OR = 0.70, 95% CI = 0.17-2.90, *P* = .623), or pN stage (OR = 1.26, 95% CI = 0.42-3.77, *P* = .675).

![Meta-analysis of the association between CAR and clinicopathological features of pancreatic cancer. (A) Gender (male vs female), (B) tumor location (head vs body or tail), (C) disease stage (metastasis vs locally advanced), and (D) pN stage (N1 vs N0).](10.1177_1559325820931290-fig4){#fig4-1559325820931290}

###### 

Meta-Analysis of Correlation Between CAR and Clinicopathological Features in Patients With Pancreatic Cancer.

![](10.1177_1559325820931290-table3)

  Clinicopathological features                     No. of studies   No. of patients   Effects model   OR (95% CI)        *P*    Heterogeneity   
  ------------------------------------------------ ---------------- ----------------- --------------- ------------------ ------ --------------- --------
  Gender (male vs female)                          6                1450              Fixed           1.38 (1.10-1.74)   .006   12.2            .337
  Tumor location (head vs body or tail)            4                1106              Fixed           0.93 (0.72-1.20)   .582   16.8            .307
  Disease stage (metastasis vs locally advanced)   2                828               Random          0.70 (0.17-2.90)   .623   93.7            \<.001
  pN stage (N1 vs N0)                              2                278               Random          1.26 (0.42-3.77)   .675   64.7            .093

Abbreviations: CAR, C-reactive protein to albumin ratio; OR, Odds ratio.

Sensitivity Analysis and Publication Bias {#section13-1559325820931290}
-----------------------------------------

Sensitivity analysis to test the stability and credibility of the results, by sequentially omitting each study showed that the results were stable ([Figure 5](#fig5-1559325820931290){ref-type="fig"}). Both Begg's funnel plot and Egger's linear regression test were applied to detect potential publication bias. The results suggested that there was no significant publication bias in this meta-analysis (Begg's *P* = .213, Egger's *P* = .431; [Figure 6](#fig6-1559325820931290){ref-type="fig"}).

![Sensitivity analysis. The plot showed the pooled hazard ratios with 95% CIs after omitting any of the studies. The elimination of any studies did not alter the statistical significance.](10.1177_1559325820931290-fig5){#fig5-1559325820931290}

![Publication bias test. (A) Begg's funnel plot for publication bias test of overall survival (*P* = .213) and (B) Egger's linear regression for publication bias test of overall survival (*P* = .431).](10.1177_1559325820931290-fig6){#fig6-1559325820931290}

Discussion {#section14-1559325820931290}
==========

Pancreatic cancer has aggressive biological behaviors, and the disease prognosis is dismal. Sensitive and effective prognostic biomarkers are helpful for the clinical management of pancreatic cancer.^[@bibr1-1559325820931290]^ The current meta-analysis pooled data from 11 studies and found that elevated CAR was predictive of poor OS, PFS, and DFS. Furthermore, a high CAR was also associated with male patients. Thus, CAR could be a reliable and easily accessible prognostic factor for patients with pancreatic cancer.

The CAR is calculated as the C-reactive protein to albumin ratio and was initially used as a long-term marker of prognosis in patients with sepsis.^[@bibr31-1559325820931290],[@bibr32-1559325820931290]^ In recent years, an increasing number of studies have investigated the prognostic role of CAR in various types of cancer^[@bibr33-1559325820931290][@bibr34-1559325820931290]-[@bibr35-1559325820931290]^ and demonstrated that pretreatment CAR is an effective predictor of poor survival. The exact mechanisms underlying the prognostic function of CAR in cancer remain to be elucidated. The possible explanations include the following: C-reactive protein (CRP) is an acute phase protein synthesized by the liver, and its level rapidly increases in response to inflammation in patients with cancer.^[@bibr36-1559325820931290]^ As a widely used inflammatory marker, elevated CRP is associated with poor prognosis in various cancers.^[@bibr37-1559325820931290][@bibr38-1559325820931290]-[@bibr39-1559325820931290]^ Albumin (Alb) is a circulating protein in the plasma and is used as a nutritional indicator. Hypoalbuminemia, as a usual symptom of chronic malnutrition, is also common in patients with cancer. Therefore, CAR, which combines CRP and Alb, has the rationale to be a prognostic indicator for patients with cancer. High CAR levels could be a marker of inferior survival outcomes in cancer.

Many recent studies have also investigated the prognostic impact of CAR on patients with diverse cancer using meta-analytic methods. A meta-analysis including 4592 patients with tumor demonstrated significantly poorer OS in patients with a high pretreatment CAR than that in those with a low CAR (HR: 2.01, 95% CI = 1.58-2.56, *P* \< .001).^[@bibr8-1559325820931290]^ Another meta-analysis also indicated that elevated CAR predicted poor OS in patients with lung cancer.^[@bibr40-1559325820931290]^ In addition, a recent meta-analysis showed that a high pretreatment CAR was associated with worse OS and DFS/PFS in patients with renal cell carcinoma (RCC), and a high CAR was also correlated with a variety of clinicopathological features.^[@bibr41-1559325820931290]^ The pooled results in the present meta-analysis on pancreatic cancer also suggested that an elevated CAR was associated with poor OS, PFS, and DFS, consistent with the findings from other types of cancer. We also found that a high CAR was associated with male sex; that is, male patients with pancreatic cancer tend to have a higher CAR. This finding may suggest that male patients are inclined to suffer from worse prognosis. Notably, in our meta-analysis, only 2 studies were conducted in Italy and Austria; the other 9 studies were performed in Korea, China, and Japan. Considering that most included studies were performed in Asia, the results of this meta-analysis could be more applicable for Asian patients with pancreatic cancer.

Although this study is the first meta-analysis on CAR in patients with pancreatic cancer, it has several limitations. First, the CAR cutoff values differed in the included studies, which may cause selection bias. The cutoff values varied from 0.0003 to 3.85 and, thus affected the stratification of patients in different studies. Second, most of the studies were from Asia. Although subgroup analysis indicated that a high CAR also predicted poor OS in Caucasian patients, more studies on patients of various ethnicities are needed. Third, the sample size for the analysis of CAR and clinical factors was small, which may account for the negative results regarding the correlation between CAR and tumor location, disease stage, and pN stage.

Conclusions {#section15-1559325820931290}
===========

In summary, the results of the current meta-analysis showed that an elevated CAR was predictive of poor prognosis in patients with pancreatic cancer. Moreover, we also found that male patients with pancreatic cancer tend to have a higher CAR. The CAR may be an effective prognostic marker for pancreatic cancer. However, due to several limitations, more large-scale studies are necessary to validate these results.
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